Bisphosphonates and other bone-strengthening medicines show very uncertain effects on lowering hip, spine, or other bone fracture risks in men at risk of fracture, according to an evidence synthesis current to October 2025. These treatments probably do not increase the overall risk of unwanted side effects compared to a placebo.
Osteoporosis and bone loss are often framed as women’s health issues following menopause. Yet, older men also experience skeletal degradation that leads to fractures of the hip and spine. Clinical literature has historically skewed toward female cohorts, leaving a gap in male-specific data.
In Plain English: The Clinical Takeaway
- Uncertain Efficacy: Current clinical trials cannot definitively prove whether bisphosphonates lower the rate of hip or spine fractures in men.
- Manageable Safety Profiles: These medications probably do not cause more frequent or severe side effects than an inactive dummy pill (placebo).
- Limited Male Data: Most bone-density research centers on postmenopausal women, meaning treatment guidelines for men rely on sparse, short-term trials.
Decoding the Clinical Evidence on Bisphosphonates
To evaluate how bone-loss treatments perform in male patients, researchers analyzed 17 distinct studies encompassing 4,132 participants with an average age ranging from 52 to 73 years. Bisphosphonates—including alendronate, risedronate, and zoledronic acid—aim to prevent fractures caused by minor falls or injuries.
The empirical findings challenge straightforward assumptions about fracture reduction. When examining hip fractures specifically, data from four trials involving 1,635 individuals showed that 0.2 percent of men taking bisphosphonates experienced a hip fracture, compared to 0.3 percent in the placebo group. This represents a 0.1 percent absolute reduction, but the underlying statistical confidence remains very low due to small sample sizes and short follow-up periods, usually capped at two years.
Similarly, data covering symptomatic spine fractures across five studies with 1,876 participants revealed that 0.4 percent of men on bisphosphonates sustained a fracture versus 0.8 percent on placebo. For non-hip, non-spine skeletal fractures, 1.6 percent of treated men experienced a break compared to 2.1 percent of the placebo cohort. In all these parameters, the confidence intervals are wide, reflecting a lack of robust statistical power in male-specific fracture trials.
Safety Profiles, Tolerability, and Alternative Therapeutics
While fracture prevention efficacy remains difficult to quantify with high certainty, safety data paints a clearer picture regarding adverse events. Bisphosphonates probably do not elevate the baseline risk of unwanted side effects. Across seven studies involving 2,548 participants, 74.6 percent of men taking bisphosphonates reported adverse events, compared to 70.4 percent in the placebo group—a 4.2 percent difference.
Furthermore, withdrawal rates due to side effects were comparable. Only 2.5 percent of men taking bisphosphonates dropped out of trials due to adverse reactions, versus 3.7 percent in the placebo arms. Serious unwanted events occurred in 27.2 percent of the bisphosphonate group and 28.6 percent of the placebo group. Alternative therapeutic classes, including parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP) analogues, denosumab, and romosozumab, yielded similar results in small-scale trials, with particularly low confidence surrounding the side-effect profiles of PTH analogues.
| Clinical Endpoint | Bisphosphonate Group (%) | Placebo Group (%) | Study Parameters |
|---|---|---|---|
| Hip Fracture Incidence | 0.2% | 0.3% | 4 studies, 1,635 participants |
| Symptomatic Spine Fracture | 0.4% | 0.8% | 5 studies, 1,876 participants |
| Other Skeletal Fractures | 1.6% | 2.1% | 6 studies, 2,043 participants |
| Any Unwanted Side Effects | 74.6% | 70.4% | 7 studies, 2,548 participants |
| Serious Adverse Events | 27.2% | 28.6% | 6 studies, 2,457 participants |
